Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:44:43 EDT Sat 05 Oct 2024
Enter Symbol
or Name
USA
CA



Q:MIRM - MIRUM PHARMACEUTICALS INC - https://mirumpharma.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MIRM - Q0.133.84·43.552.039.26-0.35-0.9278.510,7513,51539.97  40.36  39.1745.23  23.1417:00:50Sep 1015 min RT 2¢

Recent Trades - Last 10 of 3515
Time ETExPriceChangeVolume
17:00:50Q41.001.394
16:58:20Q39.26-0.352,918
16:01:26Q39.26-0.35346
16:01:20Q39.26-0.352,076
16:01:02Q39.26-0.35150
16:00:08Q39.26-0.356,399
16:00:06Q39.26-0.35106
16:00:06Q39.26-0.3515
16:00:06Q39.26-0.353,010
16:00:06Q39.26-0.3534

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-09-10 20:45U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-28 16:01U:MIRMNews ReleaseMirum Pharmaceuticals to Participate in Upcoming Investor Conferences
2024-08-09 19:00U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-07 16:01U:MIRMNews ReleaseMirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
2024-07-31 16:30U:MIRMNews ReleaseMirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
2024-07-25 08:30U:MIRMNews ReleaseMirum's LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
2024-07-10 19:00U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-07-08 08:30U:MIRMNews ReleaseMirum Pharmaceuticals' LIVMARLI Approved in the European Union for Patients with PFIC
2024-06-28 08:30U:MIRMNews ReleaseMirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX
2024-06-17 08:00U:MIRMNews ReleaseMirum's Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
2024-06-16 17:00U:MIRMNews ReleaseMirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
2024-06-10 22:00U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-06-06 09:30U:MIRMNews ReleaseLong-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
2024-06-05 16:05U:MIRMNews ReleaseMirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-31 08:30U:MIRMNews ReleaseMirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI(TM) (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
2024-05-29 08:30U:MIRMNews ReleaseLong-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
2024-05-18 07:00U:MIRMNews ReleaseMirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting
2024-05-10 19:30U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-08 16:02U:MIRMNews ReleaseMirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
2024-05-07 16:10U:MIRMNews ReleaseMirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference